Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...
X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...
In trading on Monday, shares of 10x Genomics Inc (Symbol: TXG) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $11.8955 per share. By comparison ...
On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...
In a stark reflection of the challenges facing the biotech sector, 10X Genomics Inc (NASDAQ:TXG) stock has tumbled to a 52-week low, touching down at $11.89. According to InvestingPro data, technical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results